CoreMap has announced the closure of a US$3 million series A milestone financing, with a US$20 million series B financing, which includes a diverse group of strategic, institutional, venture, and individual partners.
Pierre Jaïs of the Electrophysiology and Heart Modeling Institute and Bordeaux University Hospital (Bordeaux, France) said: “The CoreMap technology will revolutionise AF [atrial fibrillation] mapping. The ability of the Invenio catheter to record organised signals during AF is truly a quantum leap towards improving patient outcomes and holds the potential to positively impact the lives of millions of patients affected by AF.”
According to a press release from CoreMap, the financing will be used to accelerate the company’s ongoing product development efforts and initiate clinical outcome studies.
CoreMap’s technology is aimed at identifying the drivers of complex arrhythmias which will, in turn, unlock patient-specific treatment options for those suffering from AF or any complex arrhythmia. CoreMap’s patented electrode design and configuration, combined with algorithmically driven mapping and visualisation technology will enable electrophysiologists to make more informed, patient-specific therapeutic decisions to improve outcomes, the company’s release adds.
